Wikipedia -WSS

Wikipedia

author：explore 2025-09-30 22:10:17 - browse：6

Colorful broken DNA helix genome. -- health coverage from STAT — Adobe

In 2020, as biotech stocks surged amid the pandemic, a startup called Taysha Gene Therapies raised over $300 million off an audacious promise: It was going to license and develop gene therapies for at least 18 different rare and serious neurological diseases.

The effort brought hope for many rare disease families, some of whom had raised money to fund the UT-Southwestern scientist who designed the treatments after they saw no other options for their children.

Last week, the grand plan took perhaps a final blow. Taysha announced it would discontinue development of a treatment for giant axonal neuropathy, or GAN, a fatal, degenerative disease known to affect fewer than 100 people worldwide. The FDA, Taysha said, had requested an additional clinical trial that would be infeasible.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Biogen Alzheimer’s drug launch off to slow start

WSS

Independent physicians launch a new lobbying group

Medical mystery: When a cough is not just a cough

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Parkinson’s finding may lead to tests and, someday, treatments

Biden report: The neurospychology of memory and aging

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

leisure time

Wikipedia

entertainment

Psychedelics group wrestles with new pharma identity

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

At least 13 dead in Texas as scorching temps continue

Biden report: The neurospychology of memory and aging

As demand for Covid shots wanes, Moderna seeks its next success

'Revelatory' study finds a smoking impact that remains after quitting

After affirmative action ruling, medical educators look to 'holistic review'

My yearlong odyssey to get my son’s ADHD medication covered

What does generative AI mean for health care? We asked experts

The dental labor crisis is a moment of opportunity

entertainment

To avoid data mishandling cases, universities eye AI and other tools

Why doctors need education on FDA device approval process

NIH director takes cautious approach to Biden drug pricing priority

What we’ve learned from the Aduhelm mess

Eli Lilly, Pfizer, and others want in on the online prescription market

Doctors' information doesn't help them choose wisely when sick

entertainment

explore

leisure time

explore